Department of Pediatrics/Division of Genetics and Genomic Medicine, Vanderbilt University School of Medicine, DD-2205 Medical Center North, Nashville, TN 37232-2578, USA.
Pediatrics. 2011 May;127(5):e1147-53. doi: 10.1542/peds.2010-1628. Epub 2011 Apr 11.
Despite the success of childhood immunizations in prevention of infectious diseases, questions remain about the safety of vaccines in medically fragile children with inborn errors of metabolism such as urea cycle disorders (UCDs). Patients with UCDs are subject to hyperammonemic episodes (HAEs) after infection, fever, or other stressors.
We sought to assess the risk of HAEs that required urgent care or hospitalization after routine vaccinations in pediatric patients with underlying UCDs.
This was a retrospective investigation of vaccine safety in children with UCDs within the longitudinal Rare Diseases Clinical Research Consortium for UCD. Postvaccination exposure periods were defined as 7 or 21 days after any immunization. The association of vaccines and HAEs was modeled by using conditional Poisson regression, adjusting for age, and using a self-controlled case series method including all patients with ≥1 HAE and with any vaccine exposure.
The study enrolled 169 children younger than 18 years. Of these children, 74 had records of at least 1 HAE and at least 1 vaccination. With adjustment for age, there was no increase in relative incidence of HAEs in either the 7-day (1.31 [95% confidence interval (CI): 0.80-2.13]) or 21-day (1.05 [95% CI: 0.74-1.47]) exposure period after vaccination compared with HAEs outside of the vaccination periods. No vaccine type was associated with significantly more HAEs.
We found no statistically significant association between childhood immunizations and HAEs in children with UCDs. The results support the safety of immunization in this medically vulnerable population.
尽管儿童免疫接种在预防传染病方面取得了成功,但对于患有尿素循环障碍(UCD)等先天性代谢缺陷的医学脆弱儿童,疫苗的安全性仍存在疑问。患有 UCD 的患者在感染、发热或其他应激后会发生高氨血症发作(HAE)。
我们旨在评估患有基础 UCD 的儿科患者在常规疫苗接种后发生需要紧急护理或住院治疗的 HAE 的风险。
这是一项针对 UCD 纵向罕见疾病临床研究联盟中患有 UCD 的儿童疫苗安全性的回顾性研究。疫苗接种后暴露期定义为任何免疫接种后 7 或 21 天。使用条件泊松回归模型来模拟疫苗与 HAE 之间的关联,根据年龄进行调整,并使用包括所有至少发生 1 次 HAE 和任何疫苗暴露的患者的自身对照病例系列方法。
本研究纳入了 169 名年龄在 18 岁以下的儿童。其中,74 名儿童的记录中至少有 1 次 HAE 和至少 1 次疫苗接种。在调整年龄后,疫苗接种后 7 天(1.31 [95%置信区间(CI):0.80-2.13])或 21 天(1.05 [95% CI:0.74-1.47])暴露期内 HAE 的相对发生率与疫苗接种期外的 HAE 相比没有增加。没有一种疫苗类型与更多的 HAE 显著相关。
我们没有发现儿童免疫接种与 UCD 儿童 HAE 之间存在统计学显著关联。结果支持在这个医学脆弱人群中进行免疫接种的安全性。